Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction (Q43703660)

26 November 2017

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction (English)

1 reference

26 November 2017

ventricular dysfunction

1 reference

Stanek B

1

1 reference

26 November 2017

Frey B

2

1 reference

26 November 2017

Hülsmann M

3

1 reference

26 November 2017

Berger R

4

1 reference

26 November 2017

Sturm B

5

1 reference

26 November 2017

Strametz-Juranek J

6

1 reference

26 November 2017

Bergler-Klein J

7

1 reference

26 November 2017

Moser P

8

1 reference

26 November 2017

Bojic A

9

1 reference

26 November 2017

Hartter E

10

1 reference

26 November 2017

Pacher R

11

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Journal of the American College of Cardiology

26 November 2017

1 reference

26 November 2017

38

1 reference

26 November 2017

2

1 reference

26 November 2017

436-442

1 reference

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Effects of bucindolol in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2801%2901383-3

7 January 2021

10.1016/S0735-1097(01)01383-3

Identifiers

DOI

1 reference

26 November 2017

1 reference